Veradermics MANE
NYSE MANE
$127.10 +4.82 (+3.94%)
As of: Oct 20, 2026 · 3:59 PM EDT

Veradermics (MANE) Operating Leases (2025 - 2026)

Updated

Veradermics (MANE) recorded Operating Leases of $428,000 in Q2 2026.

Analysis

Veradermics (MANE) Operating Leases (2025 - 2026) Analysis & Trends

At the end of FY2025, Veradermics reported Operating Leases of $4,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn
10 Veradermics 5.17 Bn 3.77 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 428,000.00
Dec 31, 2025 4,000.00
API Access

Veradermics Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=MANE&period=max&api_key=YOUR_API_KEY